40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Whole-genome landscapes of major melanoma subtypes.

      1 , 2 , 1 , 3 , 2 , 4 , 2 , 5 , 2 , 4 , 2 , 4 , 3 , 6 , 1 , 1 , 2 , 4 , 2 , 4 , 2 , 4 , 7 , 8 , 7 , 8 , 2 , 4 , 2 , 4 , 4 , 9 , 9 , 3 , 3 , 3 , 10 , 11 , 9 , 2 , 2 , 2 , 12 , 12 , 13 , 10 , 14 , 1 , 15 , 1 , 16 , 1 , 17 , 1 , 18 , 15 , 19 , 1 , 1 , 7 , 8 , 20 , 2 , 4 ,   1 , 1 , 3 , 21 , 1 , 9
      Nature
      Springer Nature

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Melanoma of the skin is a common cancer only in Europeans, whereas it arises in internal body surfaces (mucosal sites) and on the hands and feet (acral sites) in people throughout the world. Here we report analysis of whole-genome sequences from cutaneous, acral and mucosal subtypes of melanoma. The heavily mutated landscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagenesis attributable to ultraviolet radiation. However, acral and mucosal melanomas were dominated by structural changes and mutation signatures of unknown aetiology, not previously identified in melanoma. The number of genes affected by recurrent mutations disrupting non-coding sequences was similar to that affected by recurrent mutations to coding sequences. Significantly mutated genes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma and SF3B1 in mucosal melanoma. Mutations affecting the TERT promoter were the most frequent of all; however, neither they nor ATRX mutations, which correlate with alternative telomere lengthening, were associated with greater telomere length. Most melanomas had potentially actionable mutations, most in components of the mitogen-activated protein kinase and phosphoinositol kinase pathways. The whole-genome mutation landscape of melanoma reveals diverse carcinogenic processes across its subtypes, some unrelated to sun exposure, and extends potential involvement of the non-coding genome in its pathogenesis.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

          The gradual loss of DNA from the ends of telomeres has been implicated in the control of cellular proliferative potential. Telomerase is an enzyme that restores telomeric DNA sequences, and expression of its activity was thought to be essential for the immortalization of human cells, both in vitro and in tumor progression in vivo. Telomerase activity has been detected in 50-100% of tumors of different types, but not in most normal adult somatic tissues. It has also been detected in about 70% of human cell lines immortalized in vitro and in all tumor-derived cell lines examined to date. It has previously been shown that in vitro immortalized telomerase-negative cell lines acquire very long and heterogeneous telomeres in association with immortalization presumably via one or more novel telomere-lengthening mechanisms that we refer to as ALT (alternative lengthening of telomeres). Here we report evidence for the presence of ALT in a subset of tumor-derived cell lines and tumors. The maintenance of telomeres by a mechanism other than telomerase, even in a minority of cancers, has major implications for therapeutic uses of telomerase inhibitors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Mutational signatures: the patterns of somatic mutations hidden in cancer genomes☆

            All cancers originate from a single cell that starts to behave abnormally due to the acquired somatic mutations in its genome. Until recently, the knowledge of the mutational processes that cause these somatic mutations has been very limited. Recent advances in sequencing technologies and the development of novel mathematical approaches have allowed deciphering the patterns of somatic mutations caused by different mutational processes. Here, we summarize our current understanding of mutational patterns and mutational signatures in light of both the somatic cell paradigm of cancer research and the recent developments in the field of cancer genomics.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Exome sequencing identifies GRIN2A as frequently mutated in melanoma.

              The incidence of melanoma is increasing more than any other cancer, and knowledge of its genetic alterations is limited. To systematically analyze such alterations, we performed whole-exome sequencing of 14 matched normal and metastatic tumor DNAs. Using stringent criteria, we identified 68 genes that appeared to be somatically mutated at elevated frequency, many of which are not known to be genetically altered in tumors. Most importantly, we discovered that TRRAP harbored a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 affected individuals (∼4%), as well as a previously unidentified gene, GRIN2A, which was mutated in 33% of melanoma samples. The nature, pattern and functional evaluation of the TRRAP recurrent mutation suggest that TRRAP functions as an oncogene. Our study provides, to our knowledge, the most comprehensive map of genetic alterations in melanoma to date and suggests that the glutamate signaling pathway is involved in this disease.
                Bookmark

                Author and article information

                Journal
                Nature
                Nature
                Springer Nature
                1476-4687
                0028-0836
                May 11 2017
                : 545
                : 7653
                Affiliations
                [1 ] Melanoma Institute Australia, The University of Sydney, North Sydney, Sydney, New South Wales 2065, Australia.
                [2 ] QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia.
                [3 ] Discipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.
                [4 ] Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland 4072, Australia.
                [5 ] Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland 4878, Australia.
                [6 ] Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA.
                [7 ] Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra, 08003 Barcelona, Catalonia, Spain.
                [8 ] Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain.
                [9 ] Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, Sydney, New South Wales 2145, Australia.
                [10 ] Children's Medical Research Institute, The University of Sydney, Westmead, Sydney, New South Wales 2145, Australia.
                [11 ] Children's Hospital at Westmead, The University of Sydney, Westmead, New South Wales Sydney, 2145, Australia.
                [12 ] Bioplatforms Australia, North Ryde, Sydney, New South Wales 2109, Australia.
                [13 ] University of Melbourne Centre for Cancer Research, University of Melbourne, Parkville, Melbourne, Victoria 3052, Australia.
                [14 ] School of Mathematics and Statistics, The University of Sydney, Sydney, New South Wales 2006, Australia.
                [15 ] Olivia Newton-John Cancer Research Institute, La Trobe University, Austin Health, Heidelberg, Melbourne, Victoria 3084, Australia.
                [16 ] Macquarie University, North Ryde, Sydney, New South Wales 2109, Australia.
                [17 ] Centenary Institute, The University of Sydney, Sydney, New South Wales 2006, Australia.
                [18 ] Department of Medical Oncology, Royal North Shore Hospital, St Leonards, Sydney, New South Wales 2065, Australia.
                [19 ] Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria 3000, Australia.
                [20 ] Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
                [21 ] Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales 2050, Australia.
                Article
                nature22071
                10.1038/nature22071
                28467829
                78cda53a-9e3b-497e-8a42-7545c5675f6e
                History

                Comments

                Comment on this article